Lexicon Pharmaceuticals vs Sunshine Biopharma
LXRX and SBFM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LXRX and SBFM compare
Lexicon Pharmaceuticals is the larger company, worth 77 times as much as Sunshine Biopharma ($779M against $10.1M).
Sunshine Biopharma grew revenue faster over the last twelve months (−2.7% versus −29.0% for Lexicon Pharmaceuticals).
Sunshine Biopharma keeps more of each dollar of sales as profit, with a net margin of −16.5% compared with −147% at Lexicon Pharmaceuticals.
Sunshine Biopharma scores higher on the StockData Score (10 against 5 for Lexicon Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LXRX | SBFM |
|---|---|---|
| Size and price | ||
| Market cap | $779M | $10.1M |
| Share price | $1.75 | $2.60 |
| Change, 1 year | 21.5% | −99.2% |
| Change, 5 years | −63.1% | −78.3% |
| Beta (5Y) | 0.03 | – |
| Employees | 81 | 50 |
| StockData Score | ||
| Total score | 5 | 10 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 1 |
| Performance score | 2 | 3 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 18.8× | 0.3× (better) |
| P/B | 4.5× | 0.4× (better) |
| FCF yield | – | −53.3% |
| Fair value | $0.951 | – |
| Margin of safety | −84.1% | – |
| Growth | ||
| Revenue growth (TTM) | −29.0% | −2.7% (better) |
| Revenue growth, 5Y average | 15.7% | 248% (better) |
| Profitability | ||
| Gross margin | 99.1% (better) | 30.3% |
| Operating margin | −131% | −16.6% (better) |
| Net margin | −147% | −16.5% (better) |
| FCF margin | – | −15.2% |
| Return on equity | −40.2% | −21.9% (better) |
| Return on invested capital | −163% | −31.9% (better) |
| Financial health | ||
| Debt / equity | 0.29 (better) | 0.00 |
| Current ratio | 13.37 (better) | 5.46 |
| Altman Z-score | −4.97 | −0.88 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 81.9% | 2.1% |
| Held by insiders | – | 1.8% |
| Insider net buying, 12 months | $2.8M | – |
Go deeper
- LXRX stock overview
- LXRX income statement
- LXRX valuation and score
- SBFM stock overview
- SBFM income statement
- SBFM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.